Background

In clinics, antibiotics are the preferred line of treatment for bacterial infections. However, their misuse has resulted in the emergence and rapid increase of multidrug-resistant pathogens [1,2,3,4]. A comprehensive study of 204 countries and territories estimated that there were 4.95 million deaths associated with antimicrobial resistance (AMR), which has become the third leading cause of death worldwide [5]. Furthermore, a review on AMR, commissioned by the UK government, reported that AMR-related deaths will exceed 10 million annually by 2050, surpassing cancer-related deaths [6]. The high mortality associated with drug-resistant bacterial infections is ascribed not only to the low susceptibility of these bacteria to antibiotics, but also to the high incidence of recurrent infections [7, 8]. Methicillin-resistant Staphylococcus aureus (MRSA), with a high risk of recurrence, is one of the most common drug-resistant bacteria in bacteremia, endocarditis, skin and soft tissue infections, bone and joint infections, and hospital-acquired infections [9]. Therefore, it is imperative to develop non-antibiotic therapies that integrate treatment and prevention against drug-resistant bacteria and their recurrent infections.

Bacteria-mediated therapies have attracted remarkable attention in recent years [10,11,

Conclusions

In summary, we presented a multiplex system that utilizes photothermal ablation to achieve drug-resistant bacteria abrogation, while also preventing recurrent infections with drug-resistant bacteria through adjuvant-like modulation of the host immune response. Specifically, we i) developed a PSB-based multiplex system (Rp@Al) that was fabricated through electrostatic-driven self-assembly for combating drug-resistant bacterial infections; ii) demonstrated that Rp@Al, containing BChl, which absorbs NIR light at around 805 and 865 nm, exhibited prominent photothermal properties and photothermal ablation ability toward drug-resistant bacteria; iii) revealed that Rp@Al exerts an adjuvant-like effect to enhance the antigen presentation of activated DCs, thereby priming TH1/TH2 immune responses, resulting in a protective pathogen-specific immunological memory against recurrent infections with drug-resistant bacteria; and iv) illustrated that Rp@Al not only eliminates drug-resistant bacteria through photothermal killing but also plays a preventive role in reducing infection burden and prolonging the survival period of mice during recurrent infections (Fig. 7).

Fig. 7
figure 7

Schematic illustration of PSB-based multiplex system for the treatment of drug-resistant bacterial infections. Photosynthetic bacteria (PSB)-based Rp@Al, fabricated through an electrostatic-driven self-assembly process, containing bacteriochlorophyll (BChl) that absorbs near-infrared (NIR) light at around 805 and 865 nm, exhibited effective photothermal ablation of MRSA. Rp@Al also exerted an adjuvant-like effect to enhance the antigen presentation of activated DCs, thereby priming the T helper 1 (TH1)/TH2 immune response, resulting in a protective pathogen-specific immunological memory against recurrent infections with the same drug-resistant bacteria